| Robert Joseph Fischer, MD | |
|
1st Medical Group, 45 Pine Street, Langley Afb, VA 23665-2080 | |
| (757) 764-4875 | |
| (757) 764-6843 |
| Full Name | Robert Joseph Fischer |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 1st Medical Group, Langley Afb, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093846362 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 43722-020 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robert Joseph Fischer, MD 45 Pine Street, 1st Medical Group, Langley Afb, VA 23665-2080 Ph: (757) 764-4875 | Robert Joseph Fischer, MD 1st Medical Group, 45 Pine Street, Langley Afb, VA 23665-2080 Ph: (757) 764-4875 |
News Archive
A targeted campaign of testing and counseling aimed at those who are at high risk for HIV would be more effective than the mass patient screening proposed by the Centers for Disease Control and Prevention (CDC), according to an analysis by David Holtgrave, PhD, an expert on HIV prevention at the Johns Hopkins Bloomberg School of Public Health.
An enzyme that helps maintain immune system function by "throwing away" a specific protein has a vital role in controlling symptoms of allergic asthma, new research in mice suggests.
No matter how many plastic cards currently crowd your wallet, one day you may wish to make room for one more. The Department of Homeland Security's Science and Technology Directorate has developed a miniaturized version of a dosimeter, a portable device used for measuring exposure to ionizing radiation, which can provide life-saving early detection in the unlikely event of a nuclear accident or dirty bomb.
The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.
Depression and anxiety disorders are common in patients at increased clinical risk for psychosis, but do not appear to influence transition to full-blown psychosis, say UK researchers.
› Verified 4 days ago